Yutian Feng

Journal Article Trac Trends in Analytical Chemistry · January 1, 2025 Radiopharmaceuticals are of growing interests in the development of theranostic agents and personalized medicine because of their unique advantages. Diagnosis (via molecular imaging) and treatment (via targeted radionuclide therapy) can be achieved simulta ... Full text Cite

A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation.

Journal Article Nucl Med Biol · 2024 INTRODUCTION: Targeted α-particle therapy agents have shown promising responses in patients who have developed resistance to β--particle emitting radionuclides, albeit off-target toxicity remains a concern. Astatine-211 emits only one α-particle per decay ... Full text Link to item Cite

PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.

Journal Article Nucl Med Biol · 2024 INTRODUCTION: Single domain antibody fragments (sdAbs) are an appealing scaffold for radiopharmaceutical development due to their small size (~15 kDa), high solubility, high stability, and excellent tumor penetration. Previously, we developed NB7 sdAb, whi ... Full text Link to item Cite

Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment.

Journal Article J Nucl Med · January 2023 Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy, particularly with 211At, because of their rapid accumulation in tumor and clearance from normal tissues. Here, we evaluate the therapeutic potential of this strategy w ... Full text Link to item Cite

The Radiopharmaceutical Chemistry of the Halogen Radionuclides

Chapter · January 1, 2023 Radiohalogens are far fewer in number than radiometals, yet they have been important in radiopharmaceutical therapy since the very beginning. Indeed, radionuclides of the three heaviest naturally occurring halogens-bromine, iodine, and astatine-provide rad ... Full text Cite

Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.

Journal Article J Med Chem · November 24, 2022 Because of their rapid tumor accumulation and normal tissue clearance, single-domain antibody fragments (sdAbs) are an attractive vehicle for developing radiotherapeutics labeled with the α-emitter 211At. Herein, we have evaluated iso-[211At]AGMB-PODS, a p ... Full text Link to item Cite

Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.

Journal Article Sci Rep · February 22, 2022 Radiopharmaceutical therapy (RPT) is an attractive strategy for treatment of disseminated cancers including those overexpressing the HER2 receptor including breast, ovarian and gastroesophageal carcinomas. Single-domain antibody fragments (sdAbs) exemplifi ... Full text Link to item Cite

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy.

Journal Article J Nucl Med · February 2022 α-Particle emitters targeting the prostate-specific membrane antigen (PSMA) proved effective in treating patients with prostate cancer who were unresponsive to the corresponding β-particle therapy. 211At is an α-emitter that may engender less toxicity than ... Full text Link to item Cite

A Third Generation Potentially Bifunctional Trithiol Chelate, Its nat,1XXSb(III) Complex, and Selective Chelation of Radioantimony (119Sb) from Its Sn Target.

Journal Article Inorg Chem · October 18, 2021 The therapeutic potential of the Meitner-Auger- and conversion-electron emitting radionuclide 119Sb remains unexplored because of the difficulty of incorporating it into biologically targeted compounds. To address this challenge, we report the development ... Full text Link to item Cite

A New, Second Generation Trithiol Bifunctional Chelate for 72,77As: Trithiol(b)-(Ser)2-RM2.

Journal Article Bioconjug Chem · July 21, 2021 Trithiol chelates are suitable for labeling radioarsenic (72As: 2.49 MeV β+, 26 h; 77As: 0.683 MeV β-, 38.8 h) to form potential theranostic radiopharmaceuticals for positron emission tomography (PET) imaging and therapy. A trithiol(b)-(Ser)2-RM2 bioconjug ... Full text Link to item Cite

Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.

Journal Article Nucl Med Biol · January 2021 INTRODUCTION: As a consequence of their small size, high stability and high affinity, single domain antibody fragments (sdAbs) are appealing targeting vectors for radiopharmaceutical development. With sdAbs binding to internalizing receptors like HER2, res ... Full text Link to item Cite

Production, purification and availability of 211At: Near term steps towards global access.

Journal Article Nucl Med Biol · 2021 The promising characteristics of the 7.2-h radiohalogen 211At have long been recognized; including having chemical properties suitable for labeling targeting vectors ranging from small organic molecules to proteins, and the emission of only one α-particle ... Full text Link to item Cite

Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy.

Journal Article Int J Nanomedicine · 2021 AIM: To develop an innovative 211At nanoplatform with high radiolabeling efficiency and low in vivo deastatination for future targeted alpha-particle therapy (TAT) to treat cancer. METHODS: Star-shaped gold nanoparticles, gold nanostars (GNS), were used as ... Full text Link to item Cite

Trithiol compounds—tricky but valuable: the design and synthesis of ligands for stabilizing radioarsenic for radiopharmaceutical development

Chapter · January 1, 2019 This chapter describes the development of novel trithiols for use as bifunctional chelators for no-carrier-added arsenic radioisotopes. A model trithiol (2-ethyl-2-(mercaptomethyl)propane) was synthesized with thiocyanate protecting groups, and the radioar ... Full text Cite

Evaluation of 72Se/72As generator and production of 72Se for supplying 72As as a potential PET imaging radionuclide.

Journal Article Appl Radiat Isot · January 2019 Positron-emitting 72As is the PET imaging counterpart for beta-emitting 77As. Its parent, no carrier added (n.c.a.) 72Se, was produced for a 72Se/72As generator by irradiating an enriched 7°Ge metal-graphite target via the 70Ge(α, 2 n)72Se reaction. Target ... Full text Link to item Cite

A trithiol bifunctional chelate for 72,77As: A matched pair theranostic complex with high in vivo stability.

Journal Article Nucl Med Biol · June 2018 INTRODUCTION: Trithiol chelates are suitable for labeling radioarsenic (72As: 2.49 MeV β+, 26 h; 77As: 0.683 MeV β-, 38.8 h) to form potential theranostic radiopharmaceuticals for PET imaging and therapy. To investigate the in vivo stability of trithiol ch ... Full text Link to item Cite

Chemistry and radiochemistry of As, Re and Rh isotopes relevant to radiopharmaceutical applications: high specific activity radionuclides for imaging and treatment.

Journal Article Dalton Trans · October 31, 2017 The chemistry and radiochemistry of high specific activity radioisotopes of arsenic, rhenium and rhodium are reviewed with emphasis on University of Missouri activities over the past several decades, and includes recent results. The nuclear facilities at t ... Full text Link to item Cite

Dithiol Aryl Arsenic Compounds as Potential Diagnostic and Therapeutic Radiopharmaceuticals.

Journal Article Inorg Chem · August 15, 2016 Arsenic-72 ((72)As) and (77)As have nuclear properties useful for positron emission tomography (PET) and radiotherapy, respectively. The thiophilic nature of arsenic led to the evaluation of dithioarylarsines for potential use in radiopharmaceuticals. Seve ... Full text Link to item Cite

Trithiols and their arsenic compounds for potential use in diagnostic and therapeutic radiopharmaceuticals.

Journal Article Nucl Med Biol · May 2016 INTRODUCTION: Arsenic-72 ((72)As; 2.49MeV β(+), 26h) and (77)As (0.683MeV β(-), 38.8h) have nuclear properties useful for positron emission tomography (PET) and radiotherapy applications, respectively. Their half-lives are sufficiently long for targeting t ... Full text Link to item Cite

Chromatographic separation of germanium and arsenic for the production of high purity (77)As.

Journal Article J Chromatogr A · April 8, 2016 A simple column chromatographic method was developed to isolate (77)As (94±6% (EtOH/HCl); 74±11 (MeOH)) from germanium for potential use in radioimmunotherapy. The separation of arsenic from germanium was based on their relative affinities for different ch ... Full text Link to item Cite

Synthesis and photoelectrochemical property of PbS quantum dots modified WO3 nanoflowers

Conference Ecs Transactions · January 1, 2013 PbS quantum dots modified WO3 nanoflowers were synthesized on conductive glass through a low-temperature hydrothermal process and a dip coating method. The photoelectrochenical properties of the structure were intensively studied. The results in ... Full text Cite